Ranbaxy Laboratories

Pharma major Ranbaxy Laboratories today said it expects to achieve Rs 14,000 crore (USD 3 billion) in consolidated turnover for the financial year ending December 2012.

As per its medium

Ranbaxy Laboratories today said it has failed to get the US health regulator's nod for launching generic version of Flomax, a prostrate drug, thereby missing the opportunity to launch the drug in America with exclusive marketing rights.

Driven by strong sales growth in the US, Ranbaxy Laboratories today reported a consolidated profit after tax of Rs 262 crore for the quarter ended December, 2009.

It had registered

Drug major Ranbaxy Laboratories today said it has launched a new chemical, Lulifin (Luliconazole), used in the treatment of fungal infection.

Ranbaxy Laboratories will launch parent Daiichi Sankyo's antihypertensive drug Olmesartan Medoxomil in six African countries the companies said on Monday.

Ranbaxy will launch the drug in Kenya Mozambique

Pharma company Ranbaxy Laboratories today said it has exited from Japan-based joint venture company--Nihon Pharmaceutical Industry.